Spirovant is a gene therapy company developing treatments for respiratory diseases including cystic fibrosis. The company’s current investigational gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis and other respiratory diseases. Spirovant’s lead program is in development for cystic fibrosis using our proprietary AAV + Augmenter platform
